REGN

Regeneron Pharmaceuticals, Inc.

952.70 USD
-0.10 (-0.01%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Regeneron Pharmaceuticals, Inc. stock is down -0.2% since 30 days ago. The next earnings date is May 2, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 39.39% of the previous 32 February’s closed higher than January. In the last 10 Unusual Options Trades, there were 4 PUTs, 6 CALLs. 75% of analysts rate it a buy.

Options Flow Last 10
Date & Time Expiration Date Strike Price Trade Type Size Open Interest
16 Feb 19:12 16 Aug, 2024 520.00 PUT 500 2
16 Feb 20:17 21 Jun, 2024 985.00 PUT 6 0
16 Feb 20:27 21 Jun, 2024 985.00 PUT 5 0
20 Feb 15:34 17 Jan, 2025 690.00 CALL 1 40
20 Feb 19:00 17 Jan, 2025 970.00 PUT 3 11
20 Feb 19:16 17 May, 2024 970.00 CALL 34 28
21 Feb 14:35 16 Jan, 2026 1,120.00 CALL 3 407
21 Feb 14:36 17 Jan, 2025 900.00 CALL 2 604
21 Feb 18:27 21 Jun, 2024 650.00 CALL 1 4
21 Feb 19:32 17 Jan, 2025 1,000.00 CALL 6 304

About Regeneron Pharmaceuticals, Inc.

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema. Dupixent injection is used to treat atopic dermatitis and asthma in adults and pediatrics. Kevzara solution for treating rheumatoid arthritis in adults.

  • Cantor Fitzgerald
    Tue Feb 6, 09:36
    hold
    confirm
  • RBC Capital
    Mon Feb 5, 10:32
    buy
    confirm
  • BMO Capital
    Mon Feb 5, 09:13
    buy
    confirm
  • RBC Capital
    Mon Jan 29, 12:43
    buy
    confirm